View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry


IO360° Co-hosts KOL Breakfast with Dr Carl June at J.P. Morgan 2018

  • January 8, 2018

  • Dr Carl June, The University of Pennsylvania

    IO360° is delighted to co-host with the Trout Group a KOL breakfast with immunotherapy pioneer, Dr Carl June of The University of Pennsylvania, taking place during the 36th Annual J.P. Morgan Healthcare Conference in San Francisco.

    Dr June will deliver a keynote on the CAR-T landscape and technology that is in near-term translation.

    Dr June most recently led the development of an experimental therapy for advanced childhood leukemia that become the first CAR T-cell therapy, known as Novartis’ Kymriah, to win FDA approval in August 2017.

    Novartis’ lead for Kymriah, Dr David Lebwohl, will deliver a talk on the Learnings from Kymriah – From Pivotal Trials to Launch at the IO360° conference taking place February 7-9, 2018, in NYC.

    For more information on the KOL Breakfast with Dr Carl June, contact Thomas Hoffmann at the Trout Group,

    Learn more about IO360°.